Director of the « Tissue Biology and Therapeutic Engineering » department at the IBCP (CNRS & University of Lyon).

Born in France in 1957 and trained as a chemist, before getting a phD in molecular virology in 1985 and post-doctorated for three years at the EMBL, Germany, in retroviral oncology. Then, he moved to Lyon (France) to study human retrovirology, designing HIV vaccine candidates, either therapeutic, using tat,rev or nef regulatory proteins or prophylactic, with gp140 constructs, through a permanent position at CNRS. Director of research from CNRS since 2004, he was head of a joint unit between CNRS and bioMerieux, dedicated to HIV and HCV therapeutic vaccines.

 Doctor of Medicine thesis (hepatic surgery).
– Diplomas of 3rd cycles of university studies in Marseille (Aix- Marseille II): Qualified in General Surgery, University Diploma in Anaesthesia – Intensive Care, University Diploma in Pathological Anatomy, University Diploma in Abdominal Ultrasound, University Diploma in Digestive Endoscopy.
– Diplomas of 3rd cycles of university studies in Paris (Paris XI): University Diploma in Laparoscopic Abdominal Surgery (Paris School of Surgery, Kremlin-Bicètre), University Diploma in Clinical Oncology Villejuif (IGR).

 1993: Pharmacist Diploma: six-year university degree in industrial pharmacy with honors at the University of Pharmacy of Marseille. 1998: Master degree in Sciences, speciality Biochemistry and genetics at the University of medecine of Marseille. 1999: Diplôme d’études approfondies: one-year degree before postgraduate studies in cellular and molecular biology at the University of medecine of Marseille.
RESEARCH : Study of chaperone proteins and thyroid hormonegenesis, contribution to the study of the action of the disulfide isomerase protein in the thyroglobulin metabolism. 

Master’s Degree – Magnetic Fusion Confinement Université Pierre et Marie Curie (Paris VI) 2012 – 2015

Diploma in Basic Physics International Center for Theoretical Physics Trieste, Italy 2011 – 2012

Maitrise de Physique Université Marien Ngouabi Congo 2009 – 2010

Licence de Physique Université Marien Ngouabi Congo 2008 – 2009

Passionate by science and by the universe, Olivier has obtained a PhD in quantum physics at Sorbonne Université in 2022. He has dealt with different research topics until now: particle physics and software development at CERN; foundations of quantum physics at ENS; modeling and statistics at CNRS; biology and environmental studies at AgroParisTech. Moreover, he is passionate about the crypto / blockchain ecosystem, and he is currently involved in the development of efficient crypto algorithmic bots.

Curriculum : PhD in Physics at Sorbonne Université (2019-2022).

Master in Theoretical Physics at Aix-Marseille Université (2018-2019).

Engineer School AgroParisTech (2013-2017).

ESM IAE Metz Master 2, International Finance · (2017 – 2018)

Saint Petersburg State University of Economics. Master 1 International Management · (2016 – 2017)

Université d’Angers – Bachelor of Science in Economics and International management · (2015 – 2016).

Researcher at the « Tissue Biology and Therapeutic Engineering » department at the IBCP (CNRS & University of Lyon).

Born in France in 1976 and trained as a polymer chemist, Dr. Sohier was a junior researcher in the first European tissue engineering company (IsoTis) prior to obtaining a Ph.D. in biomedical engineering from the university of Twente (Netherlands) in 2006. He then continued his studies and developments of regenerative medicine strategies in post-doctoral appointments in Nantes (Lab. of osteoarticular and dental engineering INSERM) and London (Imperial College, National Heart and Lung Institute). He has a strong interest in translating his research to patients needs and had the opportunity of participating in the creation of a startup company dedicated to bone repair, based on an innovative technology that he invented.  Since 2012, he is a permanent researcher in Lyon, where he continues to develop translatable approaches to repair and regenerate various tissues, for which there are no therapeutic alternatives.